WALTHAM,
Mass., March 1, 2024 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a clinical-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that on March 1, 2024 the Company granted inducement
awards to purchase up to 42,800 shares of common stock to three new
employees under the Company's 2023 Inducement Plan. The stock
options will vest over four years, with 25% of the underlying
shares vesting on the one-year anniversary of the vesting
commencement date and 1/48th of the underlying shares vesting
monthly thereafter over 36 months, subject to the employee's
continued service relationship with Syndax through the applicable
vesting dates.
About Syndax
Syndax is a clinical stage biopharmaceutical company developing
an innovative pipeline of cancer therapies. Highlights of the
Company's pipeline include revumenib, a highly selective inhibitor
of the Menin–KMT2A binding interaction, and axatilimab, a
monoclonal antibody that blocks the colony stimulating factor 1
(CSF-1) receptor. For more information, please visit
www.syndax.com or follow the Company on X (formerly
Twitter) and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
View original
content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302077507.html
SOURCE Syndax Pharmaceuticals, Inc.